GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT

NCT05510505 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Aplastic Anemia

Interventions

DRUG: CD20 monoclonal antibody
DRUG: ATG

Sponsor

The First Affiliated Hospital of Soochow University